- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Lakewood-Amedex Biotherapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel | 117 | PR Newswire | Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic... ► Artikel lesen | |
| 25.06. | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers | 112 | PR Newswire | Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program
SARASOTA, Fla., June 25, 2026 /PRNewswire/ --... ► Artikel lesen | |
| 17.06. | Lakewood-Amedex Biotherapeutics kündigt Aktienzusammenlegung im Verhältnis 1:10 an | 1 | Investing.com Deutsch | ||
| 17.06. | Lakewood-Amedex Biotherapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.05. | Lakewood-Amedex receives patents in Australia, New Zealand | 2 | Investing.com | ||
| LAKEWOOD-AMEDEX BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.05. | Lakewood-Amedex Biotherapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 18.05. | Lakewood-Amedex Shares Fall 20% Despite Positive Nu-3 Development Update | 12 | RTTNews | ||
| 12.05. | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 | 192 | PR Newswire | Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market
SARASOTA, Fla., May... ► Artikel lesen | |
| 01.05. | Lakewood-Amedex Biotherapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 01.05. | Lakewood-Amedex reports resistance data for diabetic ulcer drug | 2 | Investing.com | ||
| 28.04. | Lakewood-Amedex beruft CEO von Enveric in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 28.04. | Lakewood-Amedex appoints Enveric CEO to board of directors | 3 | Investing.com | ||
| 24.04. | Lakewood-Amedex-Aktie legt bei NASDAQ-Debüt um 20 % zu | 5 | Investing.com Deutsch | ||
| 23.04. | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" | 356 | PR Newswire | SARASOTA, Fla., April 23, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class... ► Artikel lesen | |
| 17.04. | Lakewood-Amedex Biotherapeutics Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 01.04. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 13.02. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 05.02. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,971 | -1,32 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,603 | -3,72 % | ACHTUNG bei InflaRx NV: Der Kurs nähert sich einer gefährlichen Marke - Das sollten Sie jetzt wissen | ||
| INTELLIA THERAPEUTICS | 9,990 | -3,57 % | Wolfe Research stuft Intellia Aktie wegen Bewertungsbedenken herab | ||
| IBIO | 1,301 | +9,79 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| IMMUNITYBIO | 6,670 | +2,46 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,520 | +3,59 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,552 | +0,23 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| IMMUNIC | 13,085 | -0,42 % | IMMUNIC, INC. - 8-K, Current Report | ||
| IOVANCE BIOTHERAPEUTICS | 4,345 | +6,76 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,100 | 0,00 % | Moleculin Biotech, Inc.: Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive... ► Artikel lesen | |
| GENPREX | 7,670 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS3724463027 Genprex Inc. 15.07.2026 US3724464017 Genprex Inc. 16.07.2026 Tausch 22:1 ► Artikel lesen | |
| MACROGENICS | 3,640 | +0,55 % | MacroGenics Completes $122.5 Million Sale Of GMP Manufacturing Operations To Bora Pharmaceuticals | ||
| MESOBLAST | 1,528 | -7,79 % | Wenn die großen Pharmakonzerne Milliarden in Krebs investieren - entsteht der nächste Zelltherapie-Boom ganz woanders? | ||
| KARYOPHARM | 8,200 | -0,61 % | Karyopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | - Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 -
- Phase 3 SENTRY Results Selected for Late-Breaking... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,274 | -2,14 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
Das Unternehmen LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.